Alumni
This person is a member of Sanger Institute Alumni.
I left Sanger Institute in July 2025, after working for two years as a Research Assistant in the Garnett laboratory. During my time at Sanger I contributed to a range of projects, including high-throughput drug screening of cancer organoid models to identify genetic features of cancer cells which are predictive of drug sensitivity, and CRISPR/Cas9 synthetic-lethal screens with the aim of identify potential new cancer drug targets.
I am now moving onto completed my PhD at The Institute of Cancer Research where I will continue to build my interests in translational cancer drug discovery. My project, Enabling Novel E3 Ligases for Targeted Protein Degradation Therapeutics, focuses on expanding the repertoire of E3 ligases that can be harnessed for targeted protein degradation, with the goal of developing new therapeutic strategies for undruggable or treatment-resistant cancer targets.
During my time at Sanger, I contributed to several key projects. I helped optimize and carry out high-throughput drug screening across large panels of cancer organoid models, working with Mosaic Therapeutics to identify genetic features predictive of drug sensitivity. I also contributed to the WRN project in partnership with GSK, which demonstrated that WRN helicase inhibitors selectively target microsatellite unstable (MSI) cancers, highlighting a potential therapeutic strategy for MSI cancer patients.
In addition I led CRISPR/Cas9 knockout screens, including the HGI and BOND projects, to identify novel genetic dependencies and prioritize promising targets for further therapeutic development.
My work supported multiple collaborations and was integral to data generation for publications currently in preparation. I am now beginning my PhD at The Institute of Cancer Research, where I will continue to build on my interest in targeted cancer therapies.